000120597 001__ 120597
000120597 005__ 20240228145455.0
000120597 0247_ $$2doi$$a10.1002/jmri.25635
000120597 0247_ $$2pmid$$apmid:28152251
000120597 0247_ $$2ISSN$$a1053-1807
000120597 0247_ $$2ISSN$$a1522-2586
000120597 0247_ $$2altmetric$$aaltmetric:16055721
000120597 037__ $$aDKFZ-2017-01025
000120597 041__ $$aeng
000120597 082__ $$a610
000120597 1001_ $$0P:(DE-HGF)0$$aWolf, Maya B$$b0$$eFirst author
000120597 245__ $$aDiffusion-weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique.
000120597 260__ $$aNew York, NY$$bWiley-Liss$$c2017
000120597 3367_ $$2DRIVER$$aarticle
000120597 3367_ $$2DataCite$$aOutput Types/Journal article
000120597 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1663660805_25469
000120597 3367_ $$2BibTeX$$aARTICLE
000120597 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120597 3367_ $$00$$2EndNote$$aJournal Article
000120597 500__ $$a2017 Sep;46(3):850-860
000120597 520__ $$aTo investigate parametric changes in the apparent diffusion coefficient (ADC) at multiple timepoints during and after completion of primary proton and carbon ion irradiation of prostate cancer (PCa) as compared with normal-appearing prostate parenchyma.In all, 92 patients with histologically confirmed PCa received either proton or carbon ion hypofractionated radiotherapy (RT). All were prospectively evaluated with diffusion-weighted magnetic resonance imaging (DWI-MRI) at five timepoints: baseline, day 10 during therapy and 6 weeks, 6 months, and 18 months after treatment. Linear mixed models (LMM) were used to evaluate the effects of radiation, antihormonal therapy, time, and type of particle irradiation on manual ADC measurements. ADC differences related to prostate-specific antigen (PSA) relapse according to PSA thresholds and to Vancouver rules and Phoenix criteria were examined using LMM and unpaired Student's t-test.A measurable and continuous increase of tumor ADC measurements from baseline (1.194 × 10(-3) mm(2) /s) during (1.350 × 10(-3) mm(2) /s, day 10, P = 0.006) and after treatment (1.355/1.430/1.490 × 10(-3) mm(2) /s, week 6 / month 6 / month 18, P = 0.001/<0.001/<0.001) was found. ADC values of normal-appearing control tissue remained unchanged. Androgen deprivation (P ≥ 0.320), different PSA thresholds (P = 0.634), and PSA relapse criteria according to Vancouver rules (P ≥ 0.776) had no effect. A weak association between 18-month measurements and Phoenix criteria (P = 0.046) was found.ADC parametric changes were distinct in tumor tissue, highlighting the ability of diffusion MRI to evaluate different aspects of the microscopic pathophysiology. Although promising, their use as noninvasive imaging biomarkers requires further validation.1 J. Magn. Reson. Imaging 2017.
000120597 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000120597 588__ $$aDataset connected to CrossRef, PubMed,
000120597 7001_ $$0P:(DE-He78)54fa6cdd5110e95e4cb5ad32fa0ea594$$aEdler, Christopher$$b1$$udkfz
000120597 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, Diana$$b2$$udkfz
000120597 7001_ $$0P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aRöthke, Matthias$$b3$$udkfz
000120597 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b4$$udkfz
000120597 7001_ $$aHerfarth, Klaus$$b5
000120597 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b6$$eLast author$$udkfz
000120597 773__ $$0PERI:(DE-600)1497154-9$$a10.1002/jmri.25635$$n3$$p850-860$$tJournal of magnetic resonance imaging$$v46$$x1053-1807$$y2017
000120597 909CO $$ooai:inrepo02.dkfz.de:120597$$pVDB
000120597 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000120597 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54fa6cdd5110e95e4cb5ad32fa0ea594$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000120597 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000120597 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000120597 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000120597 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000120597 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000120597 9141_ $$y2017
000120597 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000120597 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ MAGN RESON IMAGING : 2015
000120597 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120597 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120597 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120597 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120597 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120597 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120597 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120597 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120597 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000120597 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000120597 980__ $$ajournal
000120597 980__ $$aVDB
000120597 980__ $$aI:(DE-He78)E010-20160331
000120597 980__ $$aI:(DE-He78)C060-20160331
000120597 980__ $$aUNRESTRICTED